---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-064582"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:40:12.876428+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma gets Nasdaq extension to Sept 5, 2023 for bid price compliance

## Summary
- Nasdaq granted Benitec an additional 180-day period until Sept 5, 2023 to meet the $1.00 minimum bid price rule.
- Company failed to cure the bid price deficiency by the original deadline of March 6, 2023.
- Compliance requires closing bid price of at least $1.00 for 10 consecutive business days during extension.
- If not compliant by Sept 5, 2023, Nasdaq will begin delisting; Benitec may appeal to a hearings panel.
- Benitec may consider a reverse stock split as a potential cure for the bid price deficiency.

## SEC filing metadata
- accession: 0001193125-23-064582
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312523064582/0001193125-23-064582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312523064582/d484132d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-064582
- JSON: https://secwatch.observer/filing/0001193125-23-064582.json
- Plain text: https://secwatch.observer/filing/0001193125-23-064582.txt

## Key facts
- Listing & Compliance Notices
  Benitec Biopharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: March 7, 2023, Nasdaq notified the Company in writing that while the Company had not regained compliance with the Bid Price Rule, it was eligible for an additional 180 calendar day period, or until September 5, 2023, to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Bid Price Rule, and on the Company’s written notice to Nasdaq of its intention to cure th
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312523064582/0001193125-23-064582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.